Journals / Türk Nöroloji Dergisi / 2019 / Cilt: 25 - Sayı: 3

Determination of Factors that Impact Adherence to Warfarin in Patients with Stroke

İnmeli Hastalarda Varfarine Uyumu Etkileyen Faktörlerin Belirlenmesi

Pages
146–152
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Significant negative correlations were determined between drug adherence and age, number of risk factors, and duration of anticoagulant use (r=-0.39, r=-0.33, r=-0.52, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Oral anticoagulants are the mainstay in the secondary prevention of stroke.
📊
Key Findings & Data:A total of 99 patients with stroke who were under warfarin treatment for at least 6 months prior to the study were enrolled in the study.
💡
Conclusion & Impact:Significant negative correlations were determined between drug adherence and age, number of risk factors, and duration of anticoagulant use (r=-0.39, r=-0.33, r=-0.52, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Oral anticoagulants are the mainstay in the secondary prevention of stroke. Adherence to drug is an important issue in preventing stroke. The aimof this study was to determine the adherence of patients with stroke to warfarin (anticoagulant agent) and to investigate the factors that may impact adherence.Materials and Methods: This descriptive cross-sectional study was conducted on patients admitted to an outpatient neurology clinic of a tertiary hospital inIstanbul. A total of 99 patients with stroke who were under warfarin treatment for at least 6 months prior to the study were enrolled in the study. Patients wereassessed in terms of sociodemographic characteristics, adherence to and knowledge regarding the drug, anxiety and depression, mental and functional state andquality of life using validated scales.Results: The mean adherence score of the patients was 3.3±1.1 (0-4). The reported adherence rates were not considered as low in our sample given that 42% hadpoor knowledge. Significant negative correlations were determined between drug adherence and age, number of risk factors, and duration of anticoagulant use (r=-0.39, r=-0.33, r=-0.52, p

Özet

Amaç: Oral antikoagülanlar inmede ikincil korunmada tedavinin temelidir. İlaç tedavisine hasta uyumu, ikincil korunmada önemli konulardan biridir. Bu çalışmanın amacı inmeli hastaların varfarin (antikoagülan ajan) tedavisine uyumunu ve uyumu etkileyebilecek faktörleri belirlemektir. Gereç ve Yöntem: Bu tanımlayıcı kesitsel çalışma, İstanbul’da bir eğitim ve araştırma hastanesinin nöroloji polikliniğinde gerçekleştirilmiştir. Çalışmaya en az 6 aydır varfarin tedavisi almakta olan 99 inmeli hasta dahil edilmiştir. Hastalar sosyodemografik özellikler, ilaç uyumu ve ilaç konusunda bilgi, anksiyete ve depresyon, mental durum, fonksiyonel durum ve yaşam kalitesi faktörleri açısından değerlendirilmiştir. Bulgular: Hastaların uyum skoru 3,3±1,1 (0-4) olarak bulunmuştur. Örneklemimizin %42’si zayıf bilgi düzeyine sahip iken uyum oranları kötü olarak değerlendirilmemiştir. İlaç uyumu ile yaş, risk faktör sayısı ve antikoagülan kullanım süresi arasında istatistiksel olarak anlamlı negatif korelasyonlar saptanmıştır (r=-0,39, r=-0,33, r=-0,52, p

🔖

Cite This Article

TÜLEK, Z., DERECİ, H., ÇİFTÇİOĞLU, R. R., DÜNYA, C. P. (2022). Determination of Factors that Impact Adherence to Warfarin in Patients with Stroke. Türk Nöroloji Dergisi, Cilt: 25 - Sayı: 3, 146–152. https://ajindex.com/articles/636715

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 2017;135:146- 603
  2. Ince B. Atrial fibrillation and stroke: secondary prophylaxis. Arch Turk Soc Cardiol 2013;41:19-24
  3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation a report of the American College of Cardiology/american Heart Association task force on practice guidelines and the heart rhythm society. Circulation 2014;130:2071-2104
  4. Başaran Ö, Beton O, Doğan V, et al. ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study). Anatol J Cardiol 2016;16:734-741
  5. Potpara TS, Dan GA, Trendafilova E, et al. Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan Region: The BALKANAF Survey. Sci Rep 2016;12:20432
  6. Cruess DG, Localio AR, Platt AB, et al. Patient attitudinal and behavioral factors associated with warfarin non-adherence at outpatient anticoagulation clinics. Int J Behav Med 2010;17:33-42
  7. Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010;24:51-60
  8. Ababneh MA, Al-Azzam SI, Alzoubi KH, Rababa’h AM. Adherence in outpatients taking warfarin and its effect on anticoagulation control in Jordan. Int J Clin Pharm 2016;38:816-821
  9. Davis NJ, Billett HH, Cohen HW, Arsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother 2005;39:632- 636
  10. Hannon N, Arsava EM, Audebert HJ, et al. Antithrombotic treatment at onset of stroke with atrial fibrillation, functional outcome, and fatality: a systematic review and meta-analysis. Int J Stroke 2015;10:808-814
  11. Mayet AY. Patient adherence to warfarin therapy and its impact on anticoagulation control. Saudi Pharm J 2016;24:29-34
  12. Witt DM, Delate T, Clark NP, et al. Nonadherence with INR monitoring and anticoagulant complications. Thromb Res 2013;132:124-130
  13. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a selfreported measure of medication adherence. Med Care 1986;24:67-74
  14. Raehl CL, Bond CA, Woods T, Patry RA, Sleeper RB. Individualized drug use assessment in the elderly. Pharmacotherap 2002;22:1239-1248
  15. Gomes DC, Costa-Paiva L, Farhat FC, Pedro AO,